Functional characterization of CD8(+) antigen-specific cytotoxic T lymphocytes after enrichment based on cytokine secretion: Comparison with the MHC-tetramer technology
M. Oelke et al., Functional characterization of CD8(+) antigen-specific cytotoxic T lymphocytes after enrichment based on cytokine secretion: Comparison with the MHC-tetramer technology, SC J IMMUN, 52(6), 2000, pp. 544-549
Cell therapy with antigen-specific T cells holds promise for various diseas
es including cancer and viral infections. The powerful enrichment procedure
based on major histocompatibility complex (MHC)-tetramers, however, is of
limited applicability so far. Therefore, the recently developed cell surfac
e affinity matrix technology that allows direct identification and enrichme
nt of life antigen-specific T cells based on cytokine secretion was evaluat
ed in this respect. To this end, CD8(+) T cells directed against the HLA-A*
0201-restricted melanoma-associated peptide Melan-A (aa26-35) were generate
d by combining stimulation of peptide-pulsed autologous dendritic cells (DC
) with antigen-independent expansion with anti-CD3/anti-CD28 monoclonal ant
ibodies (MoAb). Antigen-specific cytotoxic T lympocyte (CTL) were detected
based on stimulation-induced interferon (IFN)-gamma and interleukin (IL)-4
secretion and enriched > 100-fold using the cell surface affinity matrix te
chnology. The resulting IFN-gamma- and IL-4-secreting CTL lines contained >
80% and > 70% cytokine positive T cells, respectively. They exhibited a cy
totoxic activity against Melan-A expressing target cells that was significa
ntly higher as compared to nonpurified CTL. Direct staining of enriched CTL
with HLA-A2-Melan-A-tetramers revealed a high correlation between the resu
lts obtained from the cell surface affinity matrix technology and those obt
ained from tetrameric complexes. Altogether, our study demonstrates that cy
tokine-driven enrichment based on the cell surface affinity matrix technolo
gy enables selective isolation of functionally active antigen-specific CTL
that may be used for an adoptive T cell transfer in immunotherapy.